Skip to main content

Table 3 Factors associated with postoperative cancer recurrence in patients with breast cancer after propensity score matching

From: Single dose of dexamethasone is not associated with postoperative recurrence and mortality in breast cancer patients: a propensity-matched cohort study

Variables

Univariate

Multivariate

HR

95% CI

P-value

HR

95% CI

P-value

Dexamethasone

 No

1 (ref)

   

1 (ref)

   

 Yes

1.251

0.822

1.903

0.295

1.389

0.904

2.132

0.133

Age

0.982

0.964

1.000

0.055

    

Age (years)

 < 40

1 (ref)

   

1 (ref)

   

 40–49

0.736

0.466

1.162

0.188

1.053

0.655

1.690

0.832

 50–59

0.572

0.347

0.944

0.029

0.614

0.364

1.037

0.068

 60–69

0.685

0.361

1.301

0.248

0.603

0.289

1.258

0.177

 ≥70

0.613

0.186

2.017

0.421

0.453

0.126

1.628

0.225

BMI

0.977

0.922

1.035

0.436

    

BMI (kg m−2)

 < 18.4

1.349

0.542

3.358

0.520

1.477

0.585

3.730

0.409

 18.4–22.9

1 (ref)

   

1 (ref)

   

 23–24.9

1.159

0.765

1.757

0.485

1.321

0.866

2.015

0.196

 25–29.9

0.919

0.597

1.417

0.703

1.032

0.667

1.597

0.888

 ≥30

0.326

0.045

2.353

0.266

0.345

0.047

2.524

0.295

HTN

 No

1 (ref)

   

1 (ref)

   

 Yes

1.109

0.718

1.713

0.642

1.270

0.761

2.118

0.360

DM

 No

1 (ref)

   

1 (ref)

   

 Yes

1.438

0.755

2.740

0.269

1.502

0.742

3.040

0.259

Anaesthetic agents

 TIVA

1 (ref)

   

1 (ref)

   

 Volatile

0.575

0.235

1.406

0.225

0.782

0.312

1.960

0.600

N2O

 No

1 (ref)

       

 Yes

1.515

0.919

2.497

0.103

    

Transfusion

 No

1 (ref)

       

 Yes

1.894

0.265

13.547

0.525

    

Premedicationa

 No

1 (ref)

       

 Yes

0.873

0.611

1.249

0.458

    

Surgical procedure

 BCS

1 (ref)

   

1 (ref)

   

 Mastectomy

2.119

1.458

3.078

< 0.001

1.659

1.121

2.457

0.012

TNM staging

 1

1 (ref)

   

1 (ref)

   

 2

2.454

1.503

4.006

< 0.001

2.160

1.223

3.814

0.008

 3

8.215

5.121

13.177

< 0.001

7.780

4.303

14.064

< 0.001

Oestrogen receptor

 No

1 (ref)

   

1 (ref)

   

 Yes

0.564

0.400

0.796

0.001

0.783

0.463

1.325

0.363

Progesterone receptor

 No

1 (ref)

   

1 (ref)

   

 Yes

0.572

0.407

0.803

0.001

0.818

0.491

1.363

0.441

Chemotherapy

 No

1 (ref)

   

1 (ref)

   

 Yes

1.870

1.293

2.706

0.001

0.669

0.350

1.279

0.224

Radiotherapy

 No

1 (ref)

       

 Yes

1.683

1.139

2.486

0.009

    
  1. CI confidence interval, HR hazard ratio, BMI body mass index, HTN hypertension, DM diabetes mellitus, TIVA total intravenous anaesthesia, N2O nitrous oxide, BCS breast conserving surgery, TNM tumour-node-metastasis
  2. In 1 to 5 propensity matching process, the basic characteristics of 1224 subjects in the control group were considered to be different from the dexamethasone group and excluded from the final matching analyses. Consequently, 234 patients who received dexamethasone and 1170 patients who did not receive dexamethasone were included
  3. aPremedication: Midazolam 0.03 mg kg−1 was administered
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us